Table 4.
Summary of evidence for oral and injectable alternative treatments for short-lasting unilateral neuralgiform headache attacks
| n | Outcome | Dosing details | |
|---|---|---|---|
| Topiramate | |||
| Kuhn et al. [70], Matharu et al. [71], Rossi et al. [72] | 4 | Positive 4/4 with follow-up of 5–9 months | 50–200 mg daily |
| Gabapentin | |||
| Etemadifar et al. [73] | 8 |
Positive 8/8 (5 pain free) |
600–900 mg daily |
| Carbamazepine | |||
| Matharu et al. [74]a | 33 | Complete or partial response 11/33 (alone or combination) | 600–3000 mg daily |
| Oxcarbazepine | |||
| Marziniak et al. [75], Dora [76] | 2 | Positive 2/2 with follow up 1–36 months | 600 mg daily |
| Intravenous lidocaine | |||
| Matharu et al. [77] | 4 | Positive 4/4 | 1–3 mg/min |
| Botulinum toxin | |||
| Zabalza [79] | 1 | Positive after 3 years of 3-monthly injections | Injections around orbit |
| Nerve blocks | |||
| GON | |||
| Porta-Essam et al. [80] | 1 | Positive | Bupivacaine |
| Pareja et al. [81] | 3 | Negative | Lidocaine |
| SON | |||
| Pareja et al. [81] | 7 | Negative | Lidocaine |
GON greater occipital nerve, SON supraorbital nerve
aReview article